Sucampo presents status 3 crack results of lubiprostone in non-cancer misery patients with OBD at DDW 2010
Sucampo Pharmaceuticals, Inc. today announced the awarding of results from a aspect 3 clinical shot investigating the consume of lubiprostone in non-cancer toil patients with Opioid-induced Bowel Dysfunction (OBD). These results were the course of study of an vocal unveiling at the Digestive Murrain Week (DDW) 2010 talk in Further Orleans, Louisiana, on May 5, 2010.
“We were on cloud nine to about these observations from the Time 3 results of lubiprostone in this contest as we suppose lubiprostone may stand for a tomorrow treatment scheme in support of OBD patients if approved in this firm population.”
Byron Cryer, M.D., the John C. Vanatta III Professor of Medicament at the University of Texas, Southwestern, in Dallas, Texas, who was an investigator in the woe and presented the information at DDW, said, "Opioid-induced Bowel Dysfunction in patients with dyed in the wool non-cancer irritation is a weighty question. In the Gradually eliminate 3 results of this work presented here, some patients received substitute from constipation without a reduction in their agony medication."
Gayle R. Dolecek, P.D., M.P.H., Chief Blemish President, Inquiry & Circumstance, Sucampo Pharmaceuticals, Inc., said, "We were on cloud nine to attend to these figures from the End 3 results of lubiprostone in this conditional as we assume trust to lubiprostone may picture a approaching treatment scheme in the interest OBD patients if approved in this acquiescent population."
The results reported are from a randomized, double-blind, placebo-controlled gradually eliminate 3 clinical pest (known as OBD0631) that assessed the safe keeping and efficacy of lubiprostone (24 mcg twice day after day since the treatment of OBD in patients enchanting opioids for the purpose non-cancer trial. In this lawsuit, patients with OBD were randomized to be paid either lubiprostone 24 mcg gel capsules or identical placebo capsules twice a period every epoch in spite of 12 weeks.
A sum up of 875 OBD patients with non-cancer tribulation were randomized into two identically designed aspect 3 trials. The observations reported at DDW are from united of these trials, in which statistical signification was achieved for the treatment of the primeval endpoint in equal office (OBD0631), but not in the other lessons (OBD632). Statistically weighty improvements were themselves seeing that eight of the 12 backup endpoints in research OBD0631. In den OBD0632, statistically weighty improvements were famed for the treatment of two of 12 indirect endpoints.
INCEPTION Sucampo Pharmaceuticals, Inc.,
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
